Anne W. Beaven
Distinguished in Peripheral T-Cell Lymphoma

Dr. Anne W. Beaven

Hematology Oncology | Hematology | Oncology
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
 (2347.4 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
24 Years of Experience
Distinguished in Peripheral T-Cell Lymphoma
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
 (2347.4 mi)
OverviewInsuranceLocationsClinical Research

Overview

Anne Beaven is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Beaven has been practicing medicine for over 24 years and is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Beaven is currently accepting new patients.

Her clinical research consists of co-authoring 59 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles and participated in 1 clinical trial in the study of Peripheral T-Cell Lymphoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  UnitedHealthcare
  •  Humana

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma
Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: January 17, 2025
Intervention Type: Drug, Biological
Study Drugs: CD30/CCR4 CAR-T Cells, CD30 CAR-T Cells, Bendamustine, Fludarabine
Study Phase: Phase 1
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
A Prospective Pilot Study Assessing the Immunomodulatory Effect and Clinical Activity of Programmed Cell Death Protein 1 Inhibition Following CD30 Directed Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Classical Hodgkin Lymphoma
A Prospective Pilot Study Assessing the Immunomodulatory Effect and Clinical Activity of Programmed Cell Death Protein 1 Inhibition Following CD30 Directed Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2024
Intervention Type: Biological
Study Drugs: Nivolumab, Pembrolizumab, CD30 CAR-T Cells
Study Phase: Early Phase 1
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2024
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, Ibrutinib
Study Phase: Phase 2
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 1/Phase 2
Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 31, 2020
Intervention Type: Biological
Study Phase: Phase 1
Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: March 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of the ALK Inhibitor, Ceritinib (LDK378), in Relapsed/Refractory ALK+ Hematologic Malignancies
A Phase II Study of the ALK Inhibitor, Ceritinib (LDK378), in Relapsed/Refractory ALK+ Hematologic Malignancies
Enrollment Status: Withdrawn
Publish Date: February 01, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

59 Total Publications

ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.
ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.
Journal: Transplantation and cellular therapy
Published: August 25, 2024
Similar Doctors
Advanced in Peripheral T-Cell Lymphoma
Dr. Alexandra Stefanovic
Hematology Oncology | Hematology | Oncology
Advanced in Peripheral T-Cell Lymphoma
Dr. Alexandra Stefanovic
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (9.5 mi)
919-684-8111
Languages Spoken:
English, French, German, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexandra Stefanovic is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Stefanovic and is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma (MZL), Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration. Dr. Stefanovic is currently accepting new patients.

Advanced in Peripheral T-Cell Lymphoma
Dr. Jie Z. Wang
Hematology Oncology | Oncology
Advanced in Peripheral T-Cell Lymphoma
Dr. Jie Z. Wang
Hematology Oncology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (9.5 mi)
919-684-8111
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Jie Wang is a Hematologist Oncology specialist and an Oncologist in Durham, North Carolina. Dr. Wang and is rated as an Advanced provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration. Dr. Wang is currently accepting new patients.

Advanced in Peripheral T-Cell Lymphoma
Dr. Taewoong Choi
Hematology Oncology | Hematology | Oncology
Advanced in Peripheral T-Cell Lymphoma
Dr. Taewoong Choi
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
 (9.6 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Taewoong Choi is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Choi and is rated as a Distinguished provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Choi is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile